Application of Genome-Editing Technologies for Off-the-Shelf T Cell-Based Cancer Immunotherapy
| Author | Zohreh Hakakzadeh | en |
| Author | Vahid Yekehfallah | en |
| Author | Hamidreza Ebrahimiyan | en |
| Author | Ali Sayadmanesh | en |
| Author | Mohsen Basiri | en |
| Orcid | Hamidreza Ebrahimiyan [0000-0003-0689-1281] | en |
| Orcid | Ali Sayadmanesh [0000-0003-2338-9840] | en |
| Orcid | Mohsen Basiri [0000-0003-2512-7641] | en |
| Issued Date | 2021-12-31 | en |
| Abstract | Genetically, engineered T-cell therapy is a personalized treatment that has demonstrated considerable therapeutic potential for solid tumors and hematopoietic cancers. However, endogenous T-cell receptors (TCRs) on the surface of engineered T cells hamper their application in the allogeneic settings by inducing graft-versus-host disease, where endogenous TCRs on the surface of engineered T cells respond to the recipient’s tissues. Since the cause of this allogeneic response is the TCR complex on the surface of the engineered T cells, preventing the expression of TCR components on the surface of these cells is a promising strategy to address this challenge. This review discusses the production of allogeneic chimeric antigen receptor T cells using genome-editing methods. | en |
| DOI | https://doi.org/10.5812/pmco.116796 | en |
| Keyword | Genome Editing | en |
| Keyword | Chimeric Antigen Receptor | en |
| Keyword | CRISPR | en |
| Keyword | TALEN | en |
| Keyword | ZFN | en |
| Keyword | T-Cell Receptor | en |
| Keyword | Cancer Immunotherapy | en |
| Publisher | Brieflands | en |
| Title | Application of Genome-Editing Technologies for Off-the-Shelf T Cell-Based Cancer Immunotherapy | en |
| Type | Review Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- pmco-1-1-116796.pdf
- Size:
- 926.84 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF